Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/58996
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTojo, A.en
dc.contributor.authorUsuki, K.en
dc.contributor.authorUrabe, A.en
dc.contributor.authorMaeda, Y.en
dc.contributor.authorKobayashi, Y.en
dc.contributor.authorJinnai, I.en
dc.contributor.authorOhyashiki, K.en
dc.contributor.authorNishimura, M.en
dc.contributor.authorKawaguchi, T.en
dc.contributor.authorTanaka, H.en
dc.contributor.authorMiyamura, K.en
dc.contributor.authorMiyazaki, Y.en
dc.contributor.authorHughes, T.en
dc.contributor.authorBranford, S.en
dc.contributor.authorOkamoto, S.en
dc.contributor.authorIshikawa, J.en
dc.contributor.authorOkada, M.en
dc.contributor.authorUsui, N.en
dc.contributor.authorTanii, H.en
dc.contributor.authorAmagasaki, T.en
dc.contributor.authoret al.en
dc.date.issued2009en
dc.identifier.citationInternational Journal of Hematology, 2009; 89(5):679-688en
dc.identifier.issn0925-5710en
dc.identifier.issn1865-3774en
dc.identifier.urihttp://hdl.handle.net/2440/58996-
dc.description.abstractNilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety, and pharmacokinetics of nilotinib in Japanese patients with imatinibresistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or relapsed/ refractory Ph+ acute lymphoblastic leukemia (ALL). A total of 34 patients were evaluated in this analysis and had a median duration of drug exposure of 293 (range 13–615) days. All 6 CML-CP patients without complete hematologic response (CHR) at baseline rapidly achieved CHR. A major cytogenetic response was achieved in 94% of patients with CML-CP, including a complete cytogenetic response in 69%. A major molecular response was achieved by 56%. These responses were also observed in patients with CML in advanced stages and Ph+ ALL. Non-hematologic adverse events were mostly mild to moderate. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 50 and 28% of patients, respectively. Overall, the results of this study suggest that nilotinib induced significant responses inimatinib-resistant or -intolerant patients with CML-CP and CML in advanced stages and Ph+ ALL. The results of this study confirmed the efficacy and safety of nilotinib in Japanese patients.en
dc.description.statementofresponsibilityArinobu Tojo... Timothy Hughes... Susan Branford... et al.en
dc.language.isoenen
dc.publisherGarden Jennings Publ Co Ltden
dc.rightsCopyright The Japanese Society of Hematology 2009en
dc.subjectNilotinib; CML; BCR-ABL; Imatinib resistant; Ph+ ALLen
dc.titleA Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALLen
dc.typeJournal articleen
dc.identifier.rmid0020090762en
dc.identifier.doi10.1007/s12185-009-0327-0en
dc.identifier.pubid38837-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.